∕ The shareholders of Medilab, operating under the Mediclinica brand, have decided, following several years of growth, to entrust the next phase of expansion of the network of clinics to a recognized player in the sector, Gruppo Bianalisi. This strategic decision aims to leverage Gruppo Bianalisi’s expertise to strengthen Mediclinica’s position and support its future developments.
∕ Mediclinica is a network of multidisciplinary clinics in Italy, offering a wide range of high-quality medical services. Specializing in preventive and curative medicine, the structure stands out for its personalized approach tailored to every stage of its patients’ lives. With centers in Avezzano, Cassino and L’Aquila, Mediclinica offers services ranging from specialized medicine to radiology, physiotherapy, endoscopy and medical aesthetics, guaranteeing fast, high-quality care.
Mediclinica focuses on innovation with state-of-the-art diagnostic equipment, in collaboration with over 100 doctors selected from the best Italian institutions. The range of services addresses both children and adults, offering personalized pathways according to the specific needs of different age groups, with particular emphasis on specialized services for women, men and seniors.
The clinic is also committed to health, wellness and sports programs to enhance its patients’ quality of life. This network of clinics stands out for the simplicity of its services, allowing appointments to be booked online and rapid access to medical examination results, while partnering with numerous insurance companies.
∕ Gruppo Bianalisi stands out as a leader in Italy in the field of integrated medical diagnostics, offering a wide range of services including laboratory analyses, medical imaging, specialist consultations and occupational medicine. Bianalisi collaborates with over 2,000 doctors and other healthcare professionals, consolidating its position as a benchmark in the management of diagnostic and preventive pathways.
The group is also recognized for its prevention and accessibility initiatives, having forged strategic partnerships, notably with players such as Conad, to promote health across Italy. On the financial front, Bianalisi is enjoying steady growth thanks to its strategy of targeted acquisitions, such as the recent integration of Mediclinica.
This development model is based on medical and technological innovation, aiming to offer quality care while optimizing diagnostic pathways through the use of cutting-edge technologies.
∕ Bianalisi’s acquisition of Mediclinica represents a major strategic choice, enabling it not only to consolidate its network with over 350 facilities in 12 Italian regions and San Marino, but also to add 4 million euros in sales to the 200 million already achieved by 2023. This operation is part of Bianalisi’s drive to broaden its range of services, while strengthening its partnerships with local centers of excellence, in order to diversify its activities and increase its influence in the Italian healthcare market.
A transaction led by Altios Corporate Finance
Altios Corporate Finance’s role was to support Mediclinica in its strategy of strengthening its position in Italy.
The mandate included several key phases: from identifying groups with complementary sectoral and commercial skills to those of Mediclinica, preparing detailed documentation relating to the sale project (teaser, information memorandum, valuation report, etc.), making contact with relevant acquirers, to support in the negotiation phases and overall coordination of the process through to closing.
- The role of ALTIOS Corporate Finance:
- Selection, market research, identification and qualification of potential acquirers.
- Preparation of all documentation relating to the sales process (teaser, IM, financial analysis, etc.)
- Identification of potential buyers.
- Contact with qualified buyers
- Coordination of negotiations (LOI, SPA, etc.) and due diligence.
- With the completion of this transaction, ALTIOS Corporate Finance confirms its ability to support its clients in complex sell-side operations and to successfully complete strategic transactions in Italy. ALTIOS Corporate Finance asserts itself as a renowned advisor for small and medium-sized companies.
- Altios also demonstrates its ability to build long-term relationships with its clients, enabling it to provide support as close as possible to companies’ strategic capital issues. The trusted partnership with Castaldi Partners enabled a smooth and efficient process through to closing.
Bianalisi Group statement
„ Mediclinica’s entry into our network contributes to increasing our market share, giving us access to an important new region.
The integration into our team of brilliant managers, such as Augusto Di Vossoli and Barbara Benelli, and high-level professionals who now collaborate with Mediclinica, will contribute to further improving the quality of services offered at Bianalisi’s facilities.”
Giuliano Caslini, Chairman of the Bianalisi Group
MEDILAB statement
„ The sale of Medilab and its outpatient clinics under the Mediclinica brand opens up a new phase that will benefit our patients and employees, and spur us on to do even better in the regions where we operate.”
Barbara Benelli, CFO Medilab
Advisors
Buyer’s advisors:
- Altios Corporate Finance (M&A): Mirko Mottino, Alexandre Kaplan, Edoardo Musumeci, Nicolas Vacher, Alistair Le Gras
- Clas International (DD Financial , Fiscal & ESG): Clas International – Giuseppe Cerati, Luca Laurini et Luca Zuccotti.
- Castaldi Partners (DD Legal+ SPA ): Gaspare Dori, Margherita Luppi, Alessandra Esposito Franciosi.
Contact Press: Alexandre Kaplan, M&A Director, a.kaplan@altios.com
